Dissecting the Immunobiological Effects of Bacillus Calmette-Guérin (BCG) In Vitro: Evidence of a Distinct BCG-Activated Killer (BAK) Cell Phenomenon
- 1 December 1993
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 150 (6), 1932-1937
- https://doi.org/10.1016/s0022-5347(17)35941-4
Abstract
Several immunobiological effects of intravesical bacillus Calmette-Guérin (BCG) during immunotherapy of superficial bladder cancer have been suggested as possible mediators of the mode of action. In an attempt to elucidate which of these effects is relevant to tumoricidal activity, an in vitro cytotoxicity assay was employed in which the direct effects of BCG and of cytokines against four transitional carcinoma cell lines were studied. Furthermore, peripheral blood mononuclear cells (PBMNC) were analyzed for their cytotoxic potential against these target cells. We found that none of the cytokines interleukin-1, interleukin-2, interferon-gamma, tumor necrosis factor alpha, lymphotoxin, or BCG alone were cytotoxic against the bladder carcinoma cell lines. However, a pronounced cytotoxicity against these targets resistant to natural killer cells could be induced in PBMNC by coincubation with viable BCG. We termed this the BCG-activated killer (BAK) cell phenomenon. In contrast to lymphokine-activated (LAK) cells, these BAK cells needed prolonged activation for 7 days and did not enhance the cytotoxicity against K562 target cells sensitive to natural killer cells. Nonviable, heat-inactivated BCG was significantly less effective, and sonificated fractions of BCG were not effective in stimulating PBMNC towards BAK cell activity. In vitro dissection of effects observed during BCG intravesical therapy may give more insight into the mode of action of BCG and may help to separate primary tumoricidal effector mechanisms from secondary concomitant phenomena. Further characterization of the BAK cell may result in an improvement of intravesical BCG immunotherapy.Keywords
This publication has 24 references indexed in Scilit:
- Intravesical Evans Strain BCG Therapy: Quantitative Immunohistochemical Analysis of the Immune Response within the Bladder WallJournal of Urology, 1992
- Strategy for improving therapy of superficial bladder cancerWorld Journal of Urology, 1991
- Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancerUrological Research, 1991
- Radio-Immunoassay Detection of Interferon-Gamma in Urine after Intravesical Evans BCG TherapyJournal of Urology, 1990
- Effects of Local Bacillus Calmette-Guerin Therapy in Patients with Bladder Carcinoma on Immunocompetent Cells of the Bladder WallJournal of Urology, 1990
- Elevations of Cytokines Interleukin-1, Interleukin-2 and Tumor Necrosis Factor in the Urine of Patients after Intravesical Bacillus Calmette-Guerin ImmunotherapyJournal of Urology, 1990
- Density-dependent tumor cell death and reversible cell cycle arrest: Mutually exclusive modes of monocyte-mediated growth controlExperimental Cell Research, 1990
- HLA—DR Expression by High Grade Superficial Bladder Cancer Treated with BCGBritish Journal of Urology, 1989
- Local Immune Responses after Intravesical BCG Treatment for Carcinoma in situBritish Journal of Urology, 1987
- Detection of Interleukin 2 in the Urine of Patients with Superficial Bladder Tumors after Treatment with Intravesical BCGJournal of Urology, 1986